Navigation Links
New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
Date:9/12/2007

FRIMLEY, England, September 13 /PRNewswire-FirstCall/ --

- Physicians Welcome New Option for Potentially Life Threatening Disease

- Daptomycin has a Rapidly Bactericidal Mode of Action

The launch of daptomycin for the treatment of both methicillin-sensitive and resistant Staphylococcus aureus (MSSA and MRSA) bloodstream infections (bacteraemia) and heart infections (right-sided infective endocarditis) has been announced today by Novartis Pharmaceuticals UK Ltd.(1) Daptomycin, one of only two new classes of antibiotic in over 20 years, has been shown to be as effective as existing agents in treating a range of serious Gram-positive infections, offering an important new option for healthcare professionals.

MRSA is a frequent cause of bacteraemia and is associated with serious complications, including endocarditis (in 30-40% of cases) and has a high mortality rate.(2) Over 7,000 people each year contract bacteraemia and the incidence is rising.(3) From 1993 to 2005 the number of deaths increased from 51 to 1,629.(4) There is evidence that some strains of MRSA are developing resistance to existing antibiotic options.(5) Daptomycin, which is rapidly bactericidal, has a specific mode of action, which reduces the likelihood of resistance developing. Daptomycin's once daily dosing and tolerability profile, with no need for therapeutic drug monitoring, has the potential to simplify the management of patients with complicated infections.

Dr Andrew Seaton, consultant in infectious diseases, Gartnavel general hospital, Glasgow welcomed the news, commenting; "Serious staphylococcal infections are extremely challenging for hospital specialists to treat, with about 40% in the UK now resistant to first line therapy. Daptomycin is a fast acting agent in these potentially difficult situations and is well tolerated by patients. This is an extremely important and welcomed development in the battle against serious MRSA infection."

Daptomycin is
'/>"/>

SOURCE Novartis Pharmaceuticals UK Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today ... have approved the resolutions relating to: (i) a ... units at a price of $2.67 per unit ... of one common share and 0.075358 common share ... million; and (ii) the amendment to Resverlogix,s articles ...
(Date:6/30/2015)... , June 30, 2015  NASA astronaut Kjell Lindgren ... month on his first mission to the International Space ... 8 to 9 a.m. EDT Tuesday, July 7. ... Star City, Russia . The interviews will ... Television highlighting his mission training. To schedule an ...
(Date:6/30/2015)... 2015  Today, Americord Registry, one of the fastest growing ... , a partner at Kirkland & Ellis LLP, as the ... - http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are thrilled about ... Martin Smithmyer , CEO of Americord. "He brings a ... will assist Americord,s growth and vision." Andrew ...
(Date:6/30/2015)... ... 2015 , ... With its latest polyacrylonitrile (PAN) membrane, Sterlitech ... flow rates in comparison to nylon or polyethersulfone (PES). Its unique nanofiber ... liquid flow while trapping particulates as small as 0.2 micron in width. , ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2Americord Registry Announces Andrew Horne as Advisory Board Member 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2
... Sigma Life Science, the innovative biological ... SIAL ), today announced that its SAGE Labs initiative ... (ZFN) technology to generate knock-in rats in which foreign ... genome in a precisely targeted manner.  This breakthrough achievement ...
... QuantaLife, Inc. announced today that it ... of the proceeds will be used to establish commercial ... Digital™ PCR platform, into the life sciences research market ... tests. Paladin Capital Group, together with other existing investors ...
... YORK, Dec. 10, 2010 Ramius V&O Acquisition LLC, ... that it has sent a letter to the Board ... CYPB ) outlining its willingness to acquire all of ... $5.50 per share.  The offer is conditioned upon Cypress ...
Cached Biology Technology:Sigma® Life Science Creates World's First Knock-in Rats using Zinc Finger Nuclease Technology 2Sigma® Life Science Creates World's First Knock-in Rats using Zinc Finger Nuclease Technology 3Sigma® Life Science Creates World's First Knock-in Rats using Zinc Finger Nuclease Technology 4QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet Digital™ PCR Platform and Establish Commercial Operations by 2011 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 3Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 4Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 5Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 6
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... 2013 -- An important new study has revealed the ... influences gene expression profiles of breast cancer. The ... measurements may benefit from pooling of biopsies from a ... Cancer Conference in Brussels, Belgium. These findings represent ...
... Harbor, NY When a pedestrian hears the screech of a ... to move in response. Is the action taking place blocks ... truly primal mechanisms that we depend on every day of our ... sense of hearing -- is yielding its secrets to modern neuroscience. ...
... spill in the Gulf of Mexico, crude oil toxicity ... according to new findings from a research team that ... researchers from Louisiana and South Carolina, the scientists found ... locations show developmental abnormalities, including heart defects, delayed hatching ...
Cached Biology News:Study reveals magnitude of variation in gene expression measurements within breast cancers 2Study reveals magnitude of variation in gene expression measurements within breast cancers 3Scientists discover how brain's auditory center transmits information for decisions, actions 2Scientists discover how brain's auditory center transmits information for decisions, actions 3Health defects found in fish exposed to Deepwater Horizon oil spill 2
... tubes for rodent oral gavage feature soft ... perforation and trauma. Plus they are disposable, ... the risk of cross-contamination. ... 20ga Length: ...
Adult Bovine Serum US Origin...
... 13(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 13(S)-HODE is produced by incubation of linoleic ... been shown to inhibit the adhesion of tumor ...
...
Biology Products: